Literature DB >> 23780474

Investigation of effect of variations in bone fraction and red marrow cellularity on bone marrow dosimetry in radio-immunotherapy.

S J Wilderman1, P L Roberson, W E Bolch, Y K Dewaraja.   

Abstract

A method is described for computing patient-specific absorbed dose rates to active marrow which accounts for spatial variation in bone volume fraction and marrow cellularity. A module has been added to the 3D Monte Carlo dosimetry program DPM to treat energy deposition in the components of bone spongiosa distinctly. Homogeneous voxels in regions containing bone spongiosa (as defined on CT images) are assumed to be comprised only of bone, active (red) marrow and inactive (yellow) marrow. Cellularities are determined from biopsy, and bone volume fractions are computed from cellularities and CT-derived voxel densities. Electrons are assumed to deposit energy locally in the three constituent components in proportions determined by electron energy absorption fractions which depend on energy, cellularity, and bone volume fraction, and which are either taken from the literature or are derived from Monte Carlo simulations using EGS5. Separate algorithms are used to model primary β particles and secondary electrons generated after photon interactions. Treating energy deposition distinctly in bone spongiosa constituents leads to marrow dosimetry results which differ from homogeneous spongiosa dosimetry by up to 20%. Dose rates in active marrow regions with cellularities of 20, 50, and 80% can vary by up to 20%, and can differ by up to 10% as a function of bone volume fraction. Dose to bone marrow exhibits a strong dependence on marrow cellularity and a potentially significant dependence on bone volume fraction.

Entities:  

Mesh:

Year:  2013        PMID: 23780474      PMCID: PMC3936336          DOI: 10.1088/0031-9155/58/14/4717

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  12 in total

1.  Voxel size effects in three-dimensional nuclear magnetic resonance microscopy performed for trabecular bone dosimetry.

Authors:  D A Rajon; D W Jokisch; P W Patton; A P Shah; W E Bolch
Journal:  Med Phys       Date:  2000-11       Impact factor: 4.071

2.  A hyperboliod representation of the bone-marrow interface within 3D NMR images of trabecular bone: applications to skeletal dosimetry.

Authors:  D A Rajon; A P Shah; C J Watchman; J M Brindle; W E Bolch
Journal:  Phys Med Biol       Date:  2003-06-21       Impact factor: 3.609

3.  EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.

Authors:  Cecilia Hindorf; Gerhard Glatting; Carlo Chiesa; Ola Lindén; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

4.  Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.

Authors:  Hanan Amro; Scott J Wilderman; Yuni K Dewaraja; Peter L Roberson
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

5.  An image-based skeletal dosimetry model for the ICRP reference adult male--internal electron sources.

Authors:  Matthew Hough; Perry Johnson; Didier Rajon; Derek Jokisch; Choonsik Lee; Wesley Bolch
Journal:  Phys Med Biol       Date:  2011-03-22       Impact factor: 3.609

6.  A comparison of skeletal chord-length distributions in the adult male.

Authors:  Amish P Shah; Didier A Rajon; Derek W Jokisch; Phillip W Patton; Wesley E Bolch
Journal:  Health Phys       Date:  2005-09       Impact factor: 1.316

7.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

Authors:  M S Kaminski; A D Zelenetz; O W Press; M Saleh; J Leonard; L Fehrenbacher; T A Lister; R J Stagg; G F Tidmarsh; S Kroll; R L Wahl; S J Knox; J M Vose
Journal:  J Clin Oncol       Date:  2001-10-01       Impact factor: 44.544

8.  MRI measurement of bone marrow cellularity for radiation dosimetry.

Authors:  Jose C Pichardo; Rowan J Milner; Wesley E Bolch
Journal:  J Nucl Med       Date:  2011-07-28       Impact factor: 10.057

9.  131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.

Authors:  Yuni K Dewaraja; Matthew J Schipper; Peter L Roberson; Scott J Wilderman; Hanan Amro; Denise D Regan; Kenneth F Koral; Mark S Kaminski; Anca M Avram
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

10.  An image-based skeletal tissue model for the ICRP reference newborn.

Authors:  Deanna Pafundi; Choonsik Lee; Christopher Watchman; Vincent Bourke; John Aris; Natalia Shagina; John Harrison; Tim Fell; Wesley Bolch
Journal:  Phys Med Biol       Date:  2009-06-26       Impact factor: 3.609

View more
  3 in total

1.  Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.

Authors:  Yuni K Dewaraja; Matthew J Schipper; Jincheng Shen; Lauren B Smith; Jure Murgic; Hatice Savas; Ehab Youssef; Denise Regan; Scott J Wilderman; Peter L Roberson; Mark S Kaminski; Anca M Avram
Journal:  J Nucl Med       Date:  2014-05-19       Impact factor: 10.057

2.  Evaluation of dual energy quantitative CT for determining the spatial distributions of red marrow and bone for dosimetry in internal emitter radiation therapy.

Authors:  Mitchell M Goodsitt; Apeksha Shenoy; Jincheng Shen; David Howard; Matthew J Schipper; Scott Wilderman; Emmanuel Christodoulou; Se Young Chun; Yuni K Dewaraja
Journal:  Med Phys       Date:  2014-05       Impact factor: 4.071

3.  Organ sparing of linac-based targeted marrow irradiation over total body irradiation.

Authors:  Gregory R Warrell; Valdir C Colussi; Wayne L Swanson; Paolo F Caimi; David B Mansur; Marcos J G de Lima; Gisele C Pereira
Journal:  J Appl Clin Med Phys       Date:  2019-10-11       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.